Chronic lymphocytic leukemia: treatment options for patients with refractory disease.
about
The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia.Detection of Hodgkin Transformation in a Case of Chronic Lymphocytic Leukemia by PET/CTToward personalized therapy for chronic lymphocytic leukemia: DSC and cDNA microarray assessment of two cases.Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches.Donor lymphocyte infusion followed by pentostatin, cyclophosphamide and rituximab therapy is effective for relapsed chronic lymphocytic leukemia after allogeneic stem cell transplant.
P2860
Chronic lymphocytic leukemia: treatment options for patients with refractory disease.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Chronic lymphocytic leukemia: treatment options for patients with refractory disease.
@ast
Chronic lymphocytic leukemia: treatment options for patients with refractory disease.
@en
type
label
Chronic lymphocytic leukemia: treatment options for patients with refractory disease.
@ast
Chronic lymphocytic leukemia: treatment options for patients with refractory disease.
@en
prefLabel
Chronic lymphocytic leukemia: treatment options for patients with refractory disease.
@ast
Chronic lymphocytic leukemia: treatment options for patients with refractory disease.
@en
P2860
P356
P1433
P1476
Chronic lymphocytic leukemia: treatment options for patients with refractory disease.
@en
P2093
Marina Motta
P2860
P304
P356
10.1002/CNCR.24479
P407
P577
2009-09-01T00:00:00Z